Provenge Related Published Studies
Well-designed clinical trials related to Provenge (Sipuleucel-T)
Cancer immunotherapy: sipuleucel-T and beyond. [2011.08]
Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. [2011.07.01]
Sipuleucel-T: in metastatic castration-resistant prostate cancer. [2011.01.01]
Cancer immunotherapy: sipuleucel-T and beyond. [2011]
Integrated safety data from 4 randomized, double-blind, controlled trials of
autologous cellular immunotherapy with sipuleucel-T in patients with prostate
cancer. [2011]
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. [2010.07.29]
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. [2010]
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. [2009.08.15]
Other research related to Provenge (Sipuleucel-T)
[Sipuleucel-T: a prostate cancer vaccine: "instructions for use" for urologists]. [2011.10]
Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. [2011.09]
Provenge: revolutionary technology or ethical bust? [2011.04]
Sipuleucel-T: Prototype for development of anti-tumor vaccines. [2011.04]
Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists. [2011.03]
Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm. [2011.03]
Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. [2011.02]
Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. [2011.01]
Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T? [2011.01]
Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T? [2011]
Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments. [2011]
Sipuleucel-T for the treatment of prostate cancer. [2008.04]
Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. [2008.01]
Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). [2007.08]
What happened to the Provenge (Sipuleucel-T) vaccine for hormone refractory prostate cancer? [2007.06]
Other possibly related research studies
Prostate cancer as a model for tumour immunotherapy. [2010.08]
[New drugs at the horizon for men with prostate cancer] [2010.05.26]
Adjuvants for cancer vaccines. [2010.06]
Castration-resistant prostate cancer: current and emerging treatment strategies. [2010.05.28]
Update: immunological strategies for prostate cancer. [2010.05]
Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses. [2010.05]
Current status of immunological therapies for prostate cancer. [2010.05]
Therapeutic vaccines for prostate cancer. [2010.02]
A year of successful cancer vaccines points to a path forward. [2010.02]
A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer. [2009.12]
Emerging therapies in castrate-resistant prostate cancer. [2009.05]
[Chemotherapy of hormonorefractory and hormonoresistant metastatic prostate cancer] [2008.11]
Management of hormone refractory prostate cancer. [2007.10]
Prostate cancer vaccines: current status and future potential. [2008]
Therapies in development for castrate-resistant prostate cancer. [2008.02]
Gateways to clinical trials. [2007.10]
Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). [2007.09.27]
Advances in prostate cancer immunotherapies. [2007]
New and emerging agents for the treatment of castration-resistant prostate cancer. [2011.11]
Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer. [2011.11.12]
Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). [2011.10.28]
Current Vaccination Strategies for Prostate Cancer. [2011.10.03]
New treatment options for patients with metastatic castration-resistant prostate cancer. [2011.09.22]
Second-line therapy for castrate-resistant prostate cancer: a literature review. [2011.09]
Phacilitate Barcelona active immunotherapeutics forum. 11-13 May 2011, Barcelona, Spain. [2011.08]
Immunotherapy for prostate cancer: biology and therapeutic approaches. [2011.09.20]
Immunotherapy in prostate cancer: emerging strategies against a formidable foe. [2011.09.02]
Evolving therapeutic paradigms for advanced prostate cancer. [2011.05]
Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials. [2011.06]
From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. [2011.06]
Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. [2011.06.15]
Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. [2011.06.15]
Recent advances in immunotherapy for the treatment of prostate cancer. [2011.08]
Cancer immunotherapy. [2011.07]
Updates on therapeutic targets and agents in castration-resistant prostate cancer. [2011.06]
Immunotherapy for the treatment of prostate cancer. [2011.05.24]
Current paradigms and Evolving concepts in metastatic castration-resistant prostate cancer. [2011.09]
New therapies for castration-resistant prostate cancer: efficacy and safety. [2011.08]
New options for the management of castration-resistant prostate cancer: a case perspective. [2011.02]
Current clinical trials in castrate-resistant prostate cancer. [2011.06]
[Current status and future perspective of cancer vaccine development]. [2011.04]
Current treatment strategies for castration-resistant prostate cancer. [2011.03]
Contemporary management of metastatic castration-resistant prostate cancer. [2011.05]
[Castration resistant prostate cancer 2011]. [2011.03]
Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. [2011.04]
Cancer immunotherapy. [2011.02]
Optimal management of bone metastases in prostate cancer. [2011.06]
Novel agents and new therapeutics in castration-resistant prostate cancer. [2011.05]
A renaissance in the medical treatment of advanced prostate cancer. [2010.12]
The current and emerging role of immunotherapy in prostate cancer. [2010.12.01]
Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer. [2011.01]
The application of exosomes as a nanoscale cancer vaccine. [2010.11.10]
Dendritic cell-based immunotherapy for prostate cancer. [2010]
Prostate cancer immunology - an update for Urologists. [2011.04]
Gateways to clinical trials. [2010.09]
Dendritic cells and T cells in immunotherapy. [2010.11]
Translating tumor antigens into cancer vaccines. [2011.01]
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. [2010]
Castration-resistant prostate cancer: new science and therapeutic prospects. [2010.05]
Immunotherapy for castration-resistant prostate cancer. [2012]
Management of metastatic castration-resistant prostate cancer: recent advances. [2012]
Therapeutic cancer vaccines: current status and moving forward. [2012]
Novel cancer immunotherapy agents with survival benefit: recent successes and
next steps. [2011]
Active immunotherapy for non-small-cell lung cancer: moving toward a reality. [2011]
Immunotherapy for prostate cancer: biology and therapeutic approaches. [2011]
Pharmacotherapeutic management of locally advanced prostate cancer: current
status. [2011]
Evolving standards in the treatment of docetaxel-refractory castration-resistant
prostate cancer. [2011]
Current clinical trials in castrate-resistant prostate cancer. [2011]
[Current status and future perspective of cancer vaccine development]. [Article in Japanese] [2011]
|
